You are here:

  1. NICE
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Metabolic conditions

Eliglustat for treating type 1 Gaucher disease

  • Highly specialised technologies guidance
  • Reference number: HST5
  • Published:  28 June 2017
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download Guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 The condition
  • 3 The technology
  • 4 Evidence submissions
  • 5 Consideration of the evidence
  • 6 Implementation
  • 7 Recommendations for further research
  • 8 Evaluation committee members and NICE project team

7 Recommendations for further research

7.1 The committee encourages the company, NHS England and treatment centres to collect more evidence, particularly on the longer-term benefits and costs of eliglustat and enzyme replacement therapy for treating type 1 Gaucher disease.

  • National Institute for Health and Care Excellence (NICE)

Next page 8 Evaluation committee members and NICE project team Previous page 6 Implementation